Amgen, the World's Biggest Biotechnology Group: The Competitive Strategies
|
Code : COM0110
|
Region : USA
|
||||
 |
 |
 |
 OR |
||
|
Abstract: Since its inception in 1980 as Applied Molecular Genetics Incorporated, Amgen's growth to become the world's largest biotechnology company with sales of $12.4 billion in 2005 has been phenomenal. Through its innovations, acquisition of companies like Immunex and other operational strategies, Amgen has avoided the dual menace of sluggish growth and stiff competition that has hit many pharmaceutical and biotechnological behemoths. Pedagogical Objectives: |
|
| For Case Books
Click Here >> For Case eBooks Click Here >> |
|
Keywords : Global biotechnology industry; Acquisition of Immunex; Blockbuster biopharmaceuticals and drugs; Strategic acquisitions of Amgen; Competitive Strategies Case Study; Patents of Amgen; Biotechnology drug development process; Amgen's acquisitions and partnerships; Research and development expenditure of Amgen; Eranasp; Neupogen, Enbrel, Epogen; Molecular biology
Contents :
» Amgen: The Making of the Biotechnology Behemoth
» The Competitive Landscape, Competitors and Competitive Strategies
» Amgen's Strategies to Maintain its Leadership
Contact us: IBS Case Development Centre (IBSCDC), IFHE Campus, Donthanapally, Sankarapally Road, Hyderabad-501203, Telangana, INDIA.
Mob: +91- 9640901313,
E-mail: casehelpdesk@ibsindia.org
©2020-2025 IBS Case Development Centre. All rights reserved. | Careers | Privacy Policy | Terms of Use | Disclosure | Site Map 